Theranica Announces Landmark Coverage Milestone as Nerivio® Exceeds Half of the U.S. Insured Population

Summary

Theranica announced that insurance coverage for its FDA-cleared Nerivio remote electrical neuromodulation wearable for acute and preventive migraine treatment has reached 158 million covered lives across all U.S. states, exceeding half of the nation’s insured population. The milestone follows recent payer expansions and places the non-pharmacological therapy on parity with leading prescription migraine drugs.